Publications en collaboration avec des chercheurs de Hospital Universitario Marqués de Valdecilla (11)

2019

  1. Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  2. Physical activity and breast cancer risk by pathological subtype

    Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585

2015

  1. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study

    Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795

  2. Lower breast cancer risk among women following the World Cancer Research Fund and American Institute for Cancer Research lifestyle recommendations: Epigeicam case-control study

    PLoS ONE, Vol. 10, Núm. 5

2014

  1. Spanish Mediterranean diet and other dietary patterns and breast cancer risk: Case-control EpiGEICAM study

    British Journal of Cancer, Vol. 111, pp. 1454-1462

2013

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391

  2. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212